# US 2025/0375460 A1 · Stat degraders and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375460 A1
- Document ID: US20250375460A1
- Status: Published application
- Kind: A1
- Application number: 18/876,998
- Filed: 2023-06-22
- Published: 2025-12-11
- Earliest claimed: 2022-06-22
- Assignees: Kymera Therapeutics, Inc.
- Applicants: Kymera Therapeutics, Inc.
- Inventors: Bin Yang; Lewis Dale Pennington; Eamon Comer; Melissa Ford
- Web page: https://patentgrep.com/patent/US20250375460A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 31/12: Antivirals
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07K 5/06034: {the side chain containing 2 to 4 carbon atoms}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

## Claims

### Claim 1

A compound of formula I-a:
or a pharmaceutically acceptable salt thereof, wherein:
X is —C(O)—, —C(O)NR—, —SO2—, —SO2NR—, or an optionally substituted 5-membered heterocyclic ring;
each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form an optionally substituted 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclic or heterocyclic ring having 1-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;
X1 is a covalent bond or bivalent group selected from —O—, —C(O)—, —C(S)—, —CR2—, —NR—, —S(O)—, or —SO2—;
X2 is an optionally substituted bivalent group selected from C1-6 saturated or unsaturated alkylene, phenylenyl, a 5-6 membered heteroarylenyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclylenyl or heterocyclylenyl with 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R1 is RA, —CR2RA, —OR, —SR, —NR2, —CR2OR, —CR2NR2, —CR2NRC(O)R, —CR2NRC(O)NR2, —NRC(O)OR, —NRC(O)R, —NRC(O)N(R)2, or —NRSO2R;
each RA is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R2 is hydrogen, halogen, —CN,
Ring A is a ring selected from phenyl, a 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 4 to 9-membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each of R3 is independently hydrogen, RA, halogen, —CN, —NO2, —OR, —SR, —N(R)2, —SiR3, —SO2R, —SO2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)NROR, —CR2NRC(O)R, —CR2NRC(O)NR2, —OC(O)R, —OC(O)NR2, —OP(O)R2, —OP(O)(OR)2, —OP(O)(OR)NR2, —OP(O)(NR2)2—, —NRC(O)OR, —NRC(O)R, —NRC(O)NR2, —NRSO2R, —NP(O)R2, —NRP(O)(OR)2, —NRP(O)(OR)NR2, or —NRP(O)(NR2)2; or
two R3 groups are optionally taken together to form an optionally substituted 5-7 membered partially unsaturated or aryl fused ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
m is 0, 1, 2, 4, or 5;
R4 is hydrogen, —C(O)R, —C(O)OR, —C(O)NR2, —P(O)R2, —P(O)(OR)2, —(CR2)1-3OP(O)R2, —(CR2)1-3OP(O)(OR)2, or RA;
L is a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-20 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, —O—, —NR—, —CRF—, —CF2—, —C(O)—, —S—, —S(O)—, —S(O)2—, —SiR2—, —Si(OH)R—, —Si(OH)2—, —P(O)OR—, —P(O)R—, or —P(O)NR2—, wherein:
each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
L is a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-5 hydrocarbon chain, wherein 0-3 methylene units of L are independently replaced by —O—, —NR—, —CRF—, —CF2—, —C(O)—, —S—, —S(O)—, or —S(O)2—;
Q is a bivalent moiety selected from —O—, —CR2—, —CF2—, —CFR—, —C(O)—, —OCR2—, and —C(S)—;
Y is a covalent bond or an optionally substituted —(CH2)1-3—;
Rx is hydrogen, —(CR2)1-3OCONR2, —(CR2)1-3CONR2, —(CR2)1-3SO2NR2, or RA;
Ry1 and Ry2 are each independently hydrogen, —CH2CO2R, or —CH2OCO2R, or RA;
Rz1 and Rz2 are each independently hydrogen or RA, or:
Rz1 and Rz2 are cyclically linked to form an optionally substituted fused 5-8 membered heterocyclic ring;
Ring C is an optionally substituted bivalent ring selected from phenylenyl, naphthylenyl, a 5-10 membered heteroarylenyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-11 membered saturated or partially unsaturated carbocyclylenyl or heterocyclylenyl with 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Ring E is a bivalent ring selected from phenylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl or heterocyclylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
Rw is hydrogen, RA, halogen, —CN, —NO2, —OR, —SR, —NR2, —SiR3, —S(O)2R, —S(O)2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)NROR, —CR2NRC(O)R, —CR2NRC(O)NR2, —OC(O)R, —OC(O)NR2, —OP(O)R2, —OP(O)(OR)2, —OP(O)(OR)NR2, —OP(O)(NR2)2, —NRC(O)OR, —NRC(O)R, —NRC(O)NR2, —NRS(O)2R, —NP(O)R2, —NRP(O)(OR)2, —NRP(O)(OR)NR2, or —NRP(O)(NR2)2;
w is 0, 1, 2, 3, or 4; and
n is 0 or 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is any one of the following formulae:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein X1 is selected from —CH2—,

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein X2 is selected from

### Claim 5 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, wherein L is selected from —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—,
—CH2O—, —CH2CH2O—, —CH2CH2CH2O—, —CH2CH2CH2CH2O—,

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein Q is —O—, —CF2—, or —C(O)—.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein Rz1 and Rz2 are cyclically linked to form an optionally substituted fused 5-8 membered heterocyclic ring.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein Rz1 and Rz2 are cyclically linked to form

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein Ring C is an optionally substituted bivalent ring selected from a 5-10 membered heteroarylenyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein Ring E is a bivalent ring selected from phenylenyl and a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein Rw is hydrogen, C1-6alkyl, halogen, —CN, or —OR.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein Ring E and Rw is selected from

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein said compound is selected from any one of the compounds depicted in Table 1, or a pharmaceutically acceptable salt thereof.

### Claim 14

A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
each of X, Xa, Xb, and Xd is independently a covalent bond, —O—, —C(O)—, —C(S)—, —CR2—, —NR—, —S(O)—, —SO2—, —C(O)NR—, —SO2—, —SO2NR—, —P(O)OR—, —P(O)R—, —P(O)NR2—, —OCR2—, —C(O)CR2—, —C(S)CR2—, —CR2CR2—, —NRCR2—, —S(O)CR2—, —SO2CR2—, or an optionally substituted 5-membered heterocyclic ring;
each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form an optionally substituted 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclic or heterocyclic ring having 1-3 heteroatoms, in addition to the carbon or nitrogen from which the two R groups are attached, independently selected from nitrogen, oxygen, and sulfur;
Xe is or
X1 is a covalent bond or bivalent group selected from —O—, —C(O)—, —C(S)—, —CR2—, —NR—, —S(O)—, or —SO2—;
X2 is a bivalent group selected from an optionally substituted C1-6 saturated or unsaturated alkylene or
Ring F is phenylenyl, napthylenyl, a 5-10 membered heteroarylenyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 4-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclylenyl or heterocyclylenyl with 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
Q is a bivalent group selected from a covalent bond, —O—, —CR2—, —CF2—, —CFR—, —C(O)—, —OCR2—, and —C(S)—;
R1 is RA, —CR2RA, —OR, —SR, —NR2, —CR2OR, —CR2NR2, —CR2NRC(O)R, —CR2NRC(O)NR2, —NRC(O)OR, —NRC(O)R, —NRC(O)NR2, or —NRSO2R;
each RA is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R2 is hydrogen, halogen, —CN,
each of Ring A and Ring B is independently a ring selected from phenyl, a 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 4-9 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each of Ra, Rb, Rc, Rd, Re, Re, R3 and R4 is independently hydrogen, RA, halogen, —CN, —NO2, —OR, —SR, —NR2, —SiR3, —SO2R, —SO2NR2, —S(O)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)NROR, —CR2NRC(O)R, —CR2NRC(O)NR2, —OC(O)R, —OC(O)NR2, —P(O)R2, —P(O)(OR)2, —P(O)(OR)NR2, —P(O)(NR2)2, —OP(O)R2, —OP(O)(OR)2, —OP(O)(OR)NR2, —OP(O)(NR2)2, —NRC(O)OR, —NRC(O)R, —NRC(O)NR2, —NP(O)R2, —NRP(O)(OR)2, —NRP(O)(OR)NR2, —NRP(O)(NR2)2, or —NRSO2R;
L is a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-20 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, —O—, —NR—, —CRF—, —CF2—, —C(O)—, —S—, —S(O)—, —S(O)2—, —SiR2—, —Si(OH)R—, —Si(OH)2—, —P(O)OR—, —P(O)R—, or —P(O)NR2—,
each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each of L1 and L2 is independently a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 0-3 methylene units of L1 or L2 are independently replaced by —O—, —NR—, —CR2—, —CRF—, —CF2—, —C(O)—, —S—, —S(O)—, or —S(O)2—;
Ring C is a bivalent ring selected from phenylenyl, naphthylenyl, a 5-10 membered heteroarylenyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-11 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclylenyl or heterocyclylenyl with 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Ring D is a bivalent ring selected a 5-14 membered saturated or partially unsaturated monocyclic, bicyclic, bridged bicyclic, or spirocyclic carbocyclyl or heterocyclyl with 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
Ring E is a bivalent ring selected from phenylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl or heterocyclylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
La is a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-20 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, —O—, —NR—, —S—, —P(O)(OR)—, —P(O)(R)-, —P(O)(N(R)2)—, —OC(O)—, —C(O)O—, —C(O)—, —S(O)—, —S(O)2—, —NRS(O)2—, —S(O)2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, —NRC(O)O—;
Ra is hydrogen, —CN, —CHF2, —CF3, —OR, —SR, —NR2, —N+R3, —SO2R, —SO2NR2, —S(O)R, —C(O)R, —CO2R, —C(O)NR2, —P(O)R2, —P(O)(OR)2, —P(O)(OR)NR2, —P(O)(NR2)2, or
Ring G is a ring selected from phenyl, 5-6 membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 4-9 membered saturated or partially unsaturated monocyclic, bicyclic, or bridged bicyclic carbocyclyl or heterocyclyl with 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
Rf is hydrogen, RA, halogen, —OR, —SR, —NR2, —SO2R, —SO2NR2, —S(O)R, —C(O)R, —CO2R, —C(O)NR2, —OC(O)R, —OC(O)NR2, —P(O)R2, —P(O)(OR)2, —P(O)(OR)NR2, —P(O)(NR2)2, —OP(O)R2, —OP(O)(OR)2, —OP(O)(OR)NR2, —OP(O)(NR2)2, —NRC(O)OR, —NRC(O)R, —NRC(O)NR2, —NP(O)R2, —NRP(O)(OR)2, —NRP(O)(OR)NR2, —NRP(O)(NR2)2, —C(O)P(O)R2, —C(O)P(O)(OR)2, —C(O)P(O)(OR)NR2, —C(O)P(O)(NR2)2, or —NRSO2;
b, c, d, e, f, m, n is independently 0, 1, 2, 3, or 4; and
n is 0 or 1.

### Claim 15 (depends on 14)

The compound of claim 14, wherein X1 is

### Claim 16 (depends on 14, 15)

The compound of any one of claims 14-15, wherein X2 is
and Ring F is phenylenyl.

### Claim 17 (depends on 14, 15, 16)

The compound of any one of claims 14-16, wherein Q is —C(O)—.

### Claim 18 (depends on 14, 15, 16, 17)

The compound of any one of claims 14-17, wherein R1 is —CR2NR2.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The compound of any one of claims 14-18, wherein R2 is
and Ring A is a 5-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 20 (depends on 14, 15, 16, 17, 18, 19)

The compound of any one of claims 14-19, wherein Ring B is a 5-6 membered saturated monocyclic heterocyclyl with 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The compound of any one of claims 14-20, wherein Ring C is a 9-membered heteroarylenyl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 14-21, wherein Ring D is a 1l-membered saturated bicyclic heterocyclyl with 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 23 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 14-22, wherein Ring E is phenylenyl.

### Claim 24 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound according to any one of claims 14-23, wherein L is a bivalent, saturated or partially unsaturated, straight or branched C1-10 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, —O—, —NR—, —CRF—, —CF2—, —C(O)—.

### Claim 25 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound according to any one of claims 14-24, wherein said compound is selected from any one of the compounds depicted in Table 1B, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A pharmaceutical composition comprising a compound of any one of claims 1-25, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of degrading STAT3 protein in a patient or biological sample comprising administering to said patient, or contacting said biological sample with a compound of any one of claims 1-25, or a pharmaceutical composition thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of treating an STAT3-mediated disorder, disease, or condition in a patient comprising administering to said patient a compound of any one of claims 1-25, or a pharmaceutical composition thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein the STAT3-mediated disorder, disease or condition is selected from a cancer, a neurodegenerative disease, a viral disease, an autoimmune disease, an inflammatory disorder, a hereditary disorder, a hormone-related disease, a metabolic disorder, a condition associated with organ transplantation, an immunodeficiency disorder, a destructive bone disorder, a proliferative disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, liver disease, a pathologic immune condition involving T cell activation, a cardiovascular disorder, and a CNS disorder.

### Claim 30 (depends on 29)

The method of claim 29, wherein the autoimmune disease or inflammatory disorder is selected from nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), idiopathic autoimmune hepatitis, progressive fibrosis associated interstitial lung disease, pulmonary arterial hypertension (PAH), immunoglobulin G4-related disease (IgG4-RD), chronic organ rejection (e.g., lung transplant), vasculitides (e.g., vasculitides), and STAT3 gain of function (GOF) mutations.
